In early 2021, Hemophilia Federation of America surveyed members of the bleeding disorders community to gauge their response to the COVID-19 vaccine. The survey was conducted from January 22 to March 15, 2021. For the first half of this time frame, the Pfizer and Moderna vaccines were being administered; for the second half, the Johnson and Johnson vaccine became available.
The top concerns among the bleeding disorders community about the COVID-19 vaccinations are:
- Possible side effects
- Safety of the vaccine
- Getting an allergic reaction
- Efficacy of the vaccine
- Issues with intra-muscular injection for hemophilia patients
- The rapid approval of the vaccine
Thirty-nine percent of respondents had not been vaccinated for the seasonal flu. Of those, nearly 60% said they were not likely or were very unlikely to get the flu vaccine.
This survey was the second HFA conducted as a response to the COVID-19 pandemic. Results from the first survey can be found here.